Aim: We measured carnitine levels in patients with carnitine including dialysis patients, and examined whether administration of L-carnitine improved muscle symptoms. Methods: We measured carnitine levels in 27 patients with liver cirrhosis who were receiving treatment in our hospital, and administered L-carnitine (600 mg -1800 mg) to patients having muscle cramps for approximately one month and examined the presence/absence of the symptom. We measured carnitine concentration before and after dialysis, before dialysis after the administration to eight dialysis patients, before and after the administration to 19 nondialytic patients. Results: The total carnitine levels before the dialysis of dialysis patients were an average of 42.2 μmol/L and fell to 17.7 μmol/L after more dialysis, but it was increased to 155 μmol/L after the administration of L-carnitine. In the nondialytic patients, the total carnitine levels were significantly increased from 71.7 μmol/L to 101.7 μmol/L after the administration of L-carnitine (P = 0.038). For symptomatic patients, significant improvement of muscle clamps was observed in the L-carnitine administrated group when compared with the non-administrated group (P = 0.0002). Conclusions: Total carnitine levels were low even before dialysis in the dialysis patients with liver cirrhosis in particular and they further decreased after the dialysis. Administration of L-carnitine increased the total carnitine levels and improved the symptom. Based on these results, we conclude that L-carnitine is useful for carnitine deficiency in patients with liver cirrhosis.
Introduction
In recent years, we occasionally come across some reports that carnitine is useful for improving blood ammonia and cognitive function in hepatic cirrhosis patients with latent hepatic encephalopathy [1] - [3] . Recently, levocarnitine chloride (L-Cartin® tablets 100 mg, 300 mg: Otsuka Pharmaceutical Co., Ltd., hereinafter referred to as LC) has also become available in Japan as a pharmaceutical agent for patients suspected of having carnitine deficiency. We measured serum carnitine concentrations in hepatic cirrhosis patients including dialysis patients and examined whether their cramps improved or not. Muscle spasms and hypotension during dialysis, atrophy of skeletal muscles and decrease in exercise capacity, anemia, and reduced cardiac function associated with decreased carnitine levels in dialysis patients have been reported [4] - [6] . Whereas a majority of the reports on the utility of carnitine have used supplements, we used LC for this investigation.
Methods

Patients
This was a randomized, double-blind, placebo-controlled study.
The serum carnitine concentrations in 27 patients with hepatic cirrhosis who are outpatients at our hospital were measured by using the enzyme cycling method (total carnitine reference value 45.0 -91.0 μmol/L, free carnitine reference value 36 -74 μmol/L, acylcarnitines reference value 6 -23 μmol/L). LC (600 -1800 mg) was administered to patients with cramps for 1 month, and the presence or absence of the symptom was examined. Serum carnitine concentrations were measured before and after dialysis and after LC administration in 8 dialysis patients, and before and after administration in 19 non-dialysis patients. In 17 patients with the symptom, the serum carnitine concentrations following administration were measured 1 month later. The study was reviewed and approved by the ethics committee established in the Masuko Memorial Hospital. The patients were given explanation on the study, for which written consents were obtained.
The 27 patients consisted of 8 dialysis and 19 non-dialysis patients, with no differences in the background factors (age, sex, cause, Child-Pugh grade, complication by liver cancer, implementation of dialysis, and with or without administration of branched-chain amino acids, hereinafter referred to as BCAAs, formulation) between the two groups. A significant difference was noted in serum total carnitine concentrations ( Table 1) . A significant difference was observed in serum total carnitine concentration between the dialysis patients prior to dialysis and the non-dialysis patients (42.2 ± 19.5 μmol/L vs. 70.5 ± 20.7 μmol/L, P = 0.004) (Figure 1) . In the present study, cramps, one of the symptoms experienced by patients with hepatic cirrhosis, developed in 67% (18 of 27 patients) of the patients, consisting of 50% (4 of 8 patients) of the dialysis patients and 74% (14 of 19 patients) of the non-dialysis patients (Table 2(a) ). The administration of LC caused the cramps to disappear in 92% (12 of Table 1 . The 27 patients consisted of 8 dialysis and 19 non-dialysis patients, with no differences in the background factors (age, sex, cause, Child-Pugh grade, complication by liver cancer, implementation of dialysis, and with or without administration of branched-chain amino acids, hereinafter referred to as BCAAs, formulation) between the two groups. A significant difference was noted in serum total carnitine concentrations. 
Statistical Analysis
With respect to test methods, the paired t-test and Student's t-test were used for paired continuous variable data and unpaired continuous variable data, respectively, and the chi-square test or the Fisher's exact test was used for categorical variable data. All tests were two-sided, and difference levels of p < 0.05 were considered statistically significant.
Results
Dialysis Patients
The total carnitine concentration of 6 dialysis patients whose serum carnitine concentrations were measured was a subnormal 42.2 ± 19.5 μmol/L before dialysis and 17.7 ± 6.5 μmol/L after dialysis, showing significant decrease (P = 0.011). Free carnitine levels decreased significantly from 27.0 ± 13.2 μmol/L before dialysis to 11.2 ± 25.4 μmol/L after dialysis (P = 0.009); acylcarnitine levels decreased significantly from 15.2 ± 6.2 μmol/L to 5.8 ± 1.9 μmol/L (P = 0.021) (Figure 2) . In 5 patients treated with LC, the levels of serum total carnitine, free carnitine, and acylcarnitine before and after administration increased significantly from 42.0 ± 24. 
Non-Dialysis Patients
In the non-dialysis patients, no significant differences was observed in patient backgrounds (age, sex, cause, Child-Pugh grade, complication by liver cancer, total carnitine concentration, and with or without BCAAs administration) between the LC group of 12 patients and non-administration group of 7 patients. By Child-Pugh grades, serum total carnitine showed little variation (grade A, 67.4 ± 20.4 μmol/L; grade B, 51.6 ± 18.8 μmol/L; The total carnitine concentration of 6 dialysis patients whose serum carnitine concentrations were measured was a subnormal 42.2 ± 19.5 μmol/L before dialysis and 17.7 ± 6.5 μmol/L after dialysis, showing significant decrease (P = 0.011). Free carnitine levels decreased significantly from 27.0 ± 13.2 μmol/L before dialysis to 11.2 ± 25.4 μmol/L after dialysis (P = 0.009); acylcarnitine levels decreased significantly from 15.2 ± 6.2 μmol/L to 5.8 ± 1.9 μmol/L (P = 0.021).
grade C, 71.6 ± 28.1 μmol/L); free carnitine also exhibited little variation (grade A, 51.6 ± 16.8 μmol/L; grade B, 56.3 ± 10. 9 μmol/L; grade C, 55.0 ± 18.9 μmol/L); and acylcarnitine also showed little variation (grade A, 15.8 ± 8.9 μmol/L; grade B, 18.3 ± 9.9 μmol/L; grade C, 16.6 ± 10.5 μmol/L), neither of which showed a significant difference (Figure 4) . In 12 patients treated with LC, the serum total carnitine levels before and after administrations increased significantly from 71.7 ± 22.8 μmol/L to 101.7 ± 45.5 μmol/L (P = 0.038); free carnitine increased significantly from 54.9 ± 15.4 μmol/L to 84.4 ± 36.2 μmol/L (P = 0.012); and acylcarnitine increased from 16.8 ± 9.1 μmol/L to 17.3 ± 9.8 μmol/L, showing an upward trend ( Figure 5 ). Since no improvement was observed in 1 LC-treated case (cramps developed several times monthly), the dose of LC was increased, and consequently the symptom was improved 1 month later. 
Discussion
Takayanagi reported that carnitine was an amino acid derivative with low molecular weight and played an important role in energy metabolism [7] . He presented the following three reasons for this: a) carnitine is essential for transportation of long-chain fatty acids to mitochondria; b) it adjusts the CoA/acyl-CoA ratio in mitochondria. Replacement of CoA with carnitine generates free CoA in the mitochondria; and c) carnitine removes cytotoxic acyl compounds from the cells as carnitine esters, which are excreted in the urine. Carnitine deficiency is classified into primary and secondary carnitine deficiency [8] . Primary carnitine deficiency is also known as congenital carnitine transporter deficiency or systemic carnitine deficiency. Secondary carnitine deficiency includes other inborn errors of metabolism and acquired medical conditions include: a) decrease in biosyntheses (hepatic cirrhosis, chronic kidney diseases, etc.); b) reduction in intake (long-term management of total parenteral nutrition, malnutrition, etc.); and c) reduction of body stores (pregnant and lactating women, very low birthweight infants, etc.) and those caused by medical interventions (dialysis-or drug-induced). The cases that we examined in this study were likely to have been those of secondary carnitine deficiency. The symptom of cramps in patients with hepatic cirrhosis is occasionally encountered in clinical practice, and switching therapeutic drugs from BCAA formulations or BCAA granules to oral nutrients for liver failure may improve the symptom [9] . Also, it has been reported that the causes for cramps are mechanism of peripheral neuropathy or myogenic, and decrease in blood taurine levels, which suppress abnormal excitation at the neuromuscular junction. Goto et al. discussed that BCAA formulations improved the symptom via decreased levels of free L-tryptophan caused by increased serum albumin levels, followed by facilitated ability to synthesize taurine through correction of amino acid imbalance [10] . We sometimes come across cases in which muscle symptoms occur as a result of carnitine deficiency in dialysis patients as well [11] . In 10 studies by Sakurauchi et al., LC formulation was orally administered to 30 maintenance dialysis patients at a dose of 500 mg for 12 weeks, and the patients' somatic symptoms were assessed. As a result, it was reported that muscle symptoms (including fatigue, muscle spasm, and muscle pain) had improved in two-thirds of the patients [12] . In dialysis patients who develop cramps as a result of carnitine deficiency, it is said that muscle symptoms occur due to increased burden on each cell because of insufficient energy production in the muscle cells compared to healthy individuals by shifting of the energy sources from fatty acids to sugars and proteins, which in turn are caused by decreased blood and muscle carnitine levels. It is considered that LC administration allows the long-chain fatty acids to become sufficiently available again, and the acyl compounds accumulated in the cells to be washed out by carnitine, normalizing the cells, and these factors are involved in improvement of the muscle symptoms [13] . A metaanalysis by Lynch et al. that integrated the findings of 6 studies revealed that the use of LC significantly improved muscle spasms during dialysis in 2 cases [14] . Changes in the muscle fibers in dialysis patients and carnitine deficiency are also being examined; however, no characteristic changes have been noted [15] [16] . Administration of carnitine to these patients, however, increased the long diameters of type 1 muscle fibers. In these reactions, the type 1 muscle fibers contain many mitochondria, whose metabolism is aerobic. Therefore, what obtains benefits from carnitine administration is type 1 muscle fibers; uptake of fatty acids into the mitochondria increases, cell metabolism increases, the long diameters of the muscle fibers increase, and the proportion of atrophic muscle fibers to total muscle fibers decreases [17] . Although muscle biopsies were not carried out in any of the present cases, such mechanism is likely to be responsible for the improvement in the symptom. We need to consider the doses and duration of administration in future investigations. We also need to search for alternative test items in the future because serum carnitine fractionation is currently not covered by insurance.
